Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tubercidin is a naturally occurring nucleoside antibiotic produced by Streptomyces tubericidus. It is an adenosine analog (purine ribonucleoside) that can substitute for adenosine in biological systems. Tubercidin is incorporated into DNA and RNA, where it inhibits nucleic acid metabolism by interfering with polymerases, thereby blocking DNA replication as well as RNA and protein synthesis. This mechanism underlies its antimetabolite, antineoplastic, antibacterial, antifungal, and antiparasitic activities. Tubercidin has been studied primarily in experimental settings and has not been approved for clinical use[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tubercidin.